WO2010057188A2 - Fast-acting, dietary supplement containing compositions and methods of producing the compositions - Google Patents

Fast-acting, dietary supplement containing compositions and methods of producing the compositions Download PDF

Info

Publication number
WO2010057188A2
WO2010057188A2 PCT/US2009/064803 US2009064803W WO2010057188A2 WO 2010057188 A2 WO2010057188 A2 WO 2010057188A2 US 2009064803 W US2009064803 W US 2009064803W WO 2010057188 A2 WO2010057188 A2 WO 2010057188A2
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
oral dosage
solid oral
lactase
weight
Prior art date
Application number
PCT/US2009/064803
Other languages
French (fr)
Other versions
WO2010057188A3 (en
Inventor
Trennis Lee Durham
Original Assignee
L. Perrigo Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L. Perrigo Company filed Critical L. Perrigo Company
Publication of WO2010057188A2 publication Critical patent/WO2010057188A2/en
Publication of WO2010057188A3 publication Critical patent/WO2010057188A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/20—Agglomerating; Granulating; Tabletting
    • A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • One embodiment of the present invention is generally directed toward a rapidly disintegrating solid oral dosage form that includes a lactase component containing: a lactase supplemental effective amount of a lactase enzyme, typically a ⁇ -Galactosidase; and a lactase dissolution-enhancing amount of a compressible sugar component (typically an agglomeration of sucrose and a second ingredient produced according to a co-crystallization process of a supersaturated sucrose solution and a second ingredient (the second ingredient is typically maltodextrin)) and fructose wherein the compressible sugar component and the fructose enhance the dissolution of the lactase component.
  • a lactase supplemental effective amount of a lactase enzyme typically a ⁇ -Galactosidase
  • a lactase dissolution-enhancing amount of a compressible sugar component typically an agglomeration of sucrose and a second ingredient produced according to a
  • Yet another embodiment of the present invention is generally directed toward a rapidly disintegrating solid oral dosage form that includes a lactase component having a lactase enzyme in an amount sufficient to relieve one or more symptoms of lactose intolerance in a human when the human ingests the solid oral dosage form; a disintegrant, typically a carboxymethylcellulose calcium; a compressible sugar component; a fructose; a binder; a glidant; and a lubricant.
  • the fructose and compressible sugar component are present together in an amount effective to enhance the dissolution of the lactase enzyme.
  • Another embodiment of the present invention is generally directed toward a method of making a lactase solid oral dosage form having enhanced disintegration.
  • the method typically includes the following steps and possibly others, but could consist essentially of the following steps: adding all initial dry tableting ingredients that will make up the lactase solid oral dosage form to a mixing apparatus by cross-blending the initial dry tableting ingredients or combining the initial dry tableting ingredients together; mixing the initial dry tableting ingredients together in the mixing apparatus; adding a lubricant to the initial dry tableting ingredients to form a final tableting mix; and forming the lactase solid oral dosage form having enhanced disintegration from the final tableting mix; and wherein the initial dry tableting ingredients include a lactase component, a compressible sugar component and fructose. The compressible sugar component and fructose synergistically work together to enhance the dissolution of the lactase solid oral dosage form.
  • Yet another embodiment of the present invention is generally directed toward a method for enhancing the dissolution of a hydrophilic active, typically a lactase enzyme containing component, in a dry blended and subsequently directly compressed solid oral dosage form by the incorporation of a compressible sucrose component and a fructose into the dry blended tableting mix where the compressible sucrose component and the fructose are present in a synergistically effective amount such that the dissolution of the final dosage form is enhanced versus the same dry blended and subsequently directly compressed solid oral dosage form that does not contain both the compressible sucrose component and the fructose.
  • a hydrophilic active typically a lactase enzyme containing component
  • Another embodiment of the present invention is generally directed toward a rapidly disintegrating solid oral dosage form consisting essentially of or consisting of: a lactase component having a lactase enzyme in an amount sufficient to relieve one or more symptoms of lactose intolerance in a human when the human ingests the solid oral dosage form; a disintegrant, typically carboxymethylcellulose calcium; a compressible sugar component; a fructose; a binder; a glidant; and a lubricant; where the fructose and compressible sugar component are present together in an amount effective to enhance the dissolution of the lactase enzyme.
  • An embodiment of the present invention generally includes a supplement, typically a tablet, caplet, or other solid oral dosage form, that contains compressible sugar, carboxymethylcellulose calcium, and fructose as disintegrants as well as microcrystalline cellulose as a binder/diluent, a glidant such as colloidal silicon dioxide, a lubricant, typically magnesium stearate, and an active, typically lactase.
  • a supplement typically a tablet, caplet, or other solid oral dosage form, that contains compressible sugar, carboxymethylcellulose calcium, and fructose as disintegrants as well as microcrystalline cellulose as a binder/diluent, a glidant such as colloidal silicon dioxide, a lubricant, typically magnesium stearate, and an active, typically lactase.
  • the compressible sugar and the fructose in particular the incorporation of fructose, behave as disintegrants in the supplements as opposed to functioning simply as diluents.
  • fructose was surprisingly
  • the active is lactase (an enzyme essential for digestion of lactose in milk and other dairy products such as ice cream and yogurt).
  • the lactase component is typically present in an amount of at least about 122.3 mg per caplet/tablet (about 30% to about 31%, more typically about 30.56% by weight).
  • the lactase component itself typically includes: ⁇ -Galactosidase in an amount of about 65% by weight of the lactase component; carboxymethylcellulose calcium in an amount of about 20% by weight of the lactase component; glucose in an amount of about 10% of the lactase component; and sodium citrate in an amount of about 5% of the lactase component.
  • the lactase component is typically a preblend of materials.
  • the remainder of a lactase tablet produced according to an embodiment of the present invention will include about 146 mg (about 36% by weight) of a compressible sugar component (DiPac® - direct compacting sucrose), which contains maltodextrin in an amount about 3.5% by weight of the compressible sugar component and 96.5% sucrose; about 5.8 mg (about 1.4% to about 1.5%, more typically about 1.45% by weight) carboxymethylcellulose calcium that is not a part of the lactose component but in addition to any carboxymethylcellulose calcium present in the lactase component; about 20 mg (about 4.5% to about 5.5%, more typically about 5% by weight) crystalline fructose, more typically crystalline, unmodified for direct compression fructose; about 4 mg (about 0.8% to about 1.2%, more typically about 1.0% by weight) colloidal silicon dioxide (Cab-O-Sil ® M-5P); about 100 mg (about 23% to about 27%, more typically about 25% by weight) microcrystalline a compressible sugar component (
  • the overall tablet weight may be from about 380 mg to about 420 mg, more typically from about 384 mg to about 416 mg, or even more typically about 400 mg or exactly 400 mg.
  • the amount of active lactase typically is within the range of from about 9000 to about 14,850 Units/solid oral dosage form.
  • the solid dosage form usually a caplet or tablet
  • the solid dosage form may be produced by first weighing all of the ingredients. Next, all of the dry materials except the lubricant(s), which is typically magnesium stearate, are added to a mixer through a #16 US Mesh screen. The materials may optionally be either cross-blended or combined together and thereafter mixed with one another. Once thoroughly mixed, approximately 150 revolutions in a 75 cubic foot PK mixer (about 10 to about 15 minutes), the magnesium stearate or other lubricant(s) are passed through the #16 US Mesh screen and added to the mix and the mixture is further mixed for 30 revolutions (about 2 to about 2-1/2 minutes) to form a final tableting mix.
  • the lubricant(s) which is typically magnesium stearate
  • the caplets When caplets are formed, the caplets are about 0.255 inch by 0.575 inch.
  • the thickness is typically from about 0.180 inch to about 0.2 inch.
  • the hardness is typically about 7 SCU to about 12 SCU, more typically about 10 SCU.
  • the friability of the cap let is typically no more than 1% weight loss after 4 minutes (20 tablets).
  • the compressible sugar component typically contains not less than 95.0% and not more than 98.0% sucrose, but could optionally be up to 100% sucrose or about 100% sucrose.
  • the compressible sugar component may contain minor amounts of starch, maltodextrin (a hydrolyzed starch), or invert sugar, and may contain suitable lubricant, but should not typically contain less than 95.0% sucrose.
  • One compressible sugar component of the present invention is DiPac® Direct Compacting & Tableting Sugar from Domino Foods, Inc. of Yonkers, New York and manufactured by American Sugar Refining, Inc.
  • the DiPac® Direct Compacting & Tableting Sugar is a dry fondant sugar manufactured by co-crystallization that involves the spontaneous crystallization of supersaturated sucrose solution and a second ingredient, typically maltodextrin or other partially hydrolyzed (corn) starch, by agitating it while cooling.
  • Maltodextrin typically has a Dextrose Equivalent (DE) of less than 20 and is produced by the enzymatic hydrolyzation of a starch, typically cornstarch in this case.
  • DE Dextrose Equivalent
  • the DiPac® Direct Compacting & Tableting Sugar is highly inert and will not react with moist active ingredients.
  • the DiPac® Direct Compacting & Tableting Sugar also contains no invert sugar and has less than 1% moisture.
  • the compressible sugar component will typically have the following size distribution: 3% maximum retained on a #40 (425 ⁇ m) US Mesh; 75% minimum through a #100 (150 ⁇ m) US Mesh; and 8% maximum through a #200 (75 ⁇ m) US Mesh.
  • the sucrose portion of compressible sugar is water-soluble.
  • the compressible sugar typically has a melting point of about 186 degrees Celsius.
  • compressible sugar typically has a specific surface area of from 0.13-0.14 m 2 /g.
  • the fructose of the present invention typically contains a minimum of about 99.5% fructose and a maximum of 0.05% moisture.
  • the fructose will typically have the following size distribution: 0.3% maximum retained on a #20 US Mesh screen; 1.0% maximum retained on a #30 US Mesh screen; 20% maximum retained on a #40 US Mesh screen; 45% minimum to 75% maximum retained on a #60 US Mesh screen; and 8.0% maximum percent through a #100 US Mesh screen.
  • the fructose typically has a loose bulk density of 0.80-0.88 gm/ml.
  • the compressible sugar and the fructose provide enhanced disintegration of the solid oral dosage form, typically a caplet or tablet.
  • fructose enhances the dissolution of hydrophilic actives, in particular lactase.
  • Compressible sugar and fructose are conventionally utilized as diluents or sweeteners in tablet formulations.
  • these two components seem to behave synergistically in the presence of one another in a solid dosage form, to facilitate disintegration of the tablet/caplet or other solid dosage form containing the hydrophilic active or hydrophilic actives.
  • Carboxymethylcellulose calcium is a disintegrant that works in conjunction with the compressible sugar/fructose.
  • Carboxymethylcellulose calcium is hygroscopic and usually has a particle distribution of 95% through a 73.7 ⁇ m sieve (#200 Mesh).
  • microcrystalline cellulose is a purified, partially depolymerized cellulose. It is practically insoluble in water.
  • CAB-O-SIL® from Cabot Corporation, is an untreated amorphous fumed silica that is a high purity silica manufactured by high temperature hydrolysis of chlorosilanes in a hydrogen/oxygen flame.
  • Colloidal silicon dioxides have extremely small particle sizes and varying surface areas.
  • the typical colloidal silicon dioxide used in an embodiment of the present invention has a particle size of from 0.2-0.3 microns and a surface area of from 200 ⁇ 25 m 2 /g.
  • Lactase produced commercially can be extracted both from yeasts such as
  • lactase used in accordance with the present invention is extracted from Aspergillus oryzae.
  • the lactase used in a lactase supplement embodiment of the present invention is typically hydrophilic.
  • the lactase enzyme is typically ⁇ -Galactosidase.
  • compositions of the present invention at least have a faster initial dissolution rate in the first one minute to five minute time frame and have a greater overall dissolution of the active on and after 45 minutes.
  • Product A contained the following ingredients: lactase, microcrystalline cellulose, croscarmellose sodium, crospovidone, colloidal silicon dioxide, and magnesium stearate.
  • Product D contained the following ingredients: mannitol (70.2% by weight); microcrystalline cellulose (17.8% by weight); lactase (7.2% by weight); carboxymethylcellulose calcium (2.2% by weight); glucose (1.1% by weight); magnesium stearate (1.0% by weight); and sodium citrate (0.5% by weight).
  • the Example of Table I is an embodiment of the present invention and contains the following ingredients in approximately the following amounts: sucrose (about 35.2% by weight); microcrystalline cellulose (about 25% by weight); lactase enzyme (about 19.9% by weight); carboxymethylcellulose calcium (about 7.6% by weight); fructose (about 5% by weight); glucose (about 3.1% by weight); sodium citrate (about 1.5% by weight); maltodextrin (about 1.3% by weight); silicon dioxide (about 1% by weight) and magnesium stearate (about 0.5% by weight).
  • sucrose about 35.2% by weight
  • microcrystalline cellulose about 25% by weight
  • lactase enzyme about 19.9% by weight
  • carboxymethylcellulose calcium about 7.6% by weight
  • fructose about 5% by weight
  • glucose about 3.1% by weight
  • sodium citrate about 1.5% by weight
  • maltodextrin about 1.3% by weight
  • silicon dioxide about 1% by weight
  • magnesium stearate about 0.5% by weight
  • the test method combines the FCC test method for Lactase Enzyme Activity with the USP Dissolution Performance testing as a means to measure the rate of performance of the lactase enzyme.
  • the FCC reference method is: Food Chemical Codex (FCC); Fifth Edition; General Tests and Assays, Appendix V, Pages 913-914; Lactase (Acid) Beta- Galactosidase Activity.
  • the USP dissolution reference method is: USP 30/NF 25 Volume 1; 2007; ⁇ 711 dissolution Apparatus 1.
  • the method determines lactase ( ⁇ -Galactosidase) activity in dietary supplements.
  • the assay is based on a 15-min hydrolysis of an o-nitrophenyl-B-D- galactopyranoside substrate at 37°C and pH 4.5.
  • the o-nitrophenol released on hydrolysis of the o-nitrophenyl-B-D-galactopyranoside substrate is determined spectrophotometrically.
  • a fresh tablet of one product is placed in the dissolution vessel.
  • the tablet is allowed to sink to the bottom of the vessel.
  • a fresh tablet of 1 product is placed in the dissolution vessel.
  • a fresh tablet of 1 product is placed in the dissolution vessel.
  • the tablet is allowed to sink to the bottom of the vessel.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

A rapidly disintegrating solid oral dosage form that includes a lactase component containing: a lactase supplemental effective amount of a lactase enzyme, typically a ß galactosidase; and a lactase dissolution-enhancing amount of a compressible sugar component (typically an agglomeration of sucrose and maltodextrin produced according to a co-crystallization process of a supersaturated sucrose solution and a second ingredient (the second ingredient is typically maltodextrin or another modified starch)) and fructose where the compressible sugar component and the fructose enhance the dissolution of the lactase component.

Description

FAST-ACTING, DIETARY SUPPLEMENT CONTAINING COMPOSITIONS AND METHODS OF PRODUCING THE COMPOSITIONS
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims priority under 35 U.S. C. § 119(e) and the benefit of U.S.
Provisional Patent Application No. 61/115,325, entitled "FAST-ACTING, DIETARY SUPPLEMENT CONTAINING COMPOSITIONS AND METHODS OF PRODUCING THE COMPOSITIONS," filed on November 17, 2008, the entire disclosure of which is incorporated herein by reference.
BRIEF SUMMARY OF THE INVENTION
[0002] One embodiment of the present invention is generally directed toward a rapidly disintegrating solid oral dosage form that includes a lactase component containing: a lactase supplemental effective amount of a lactase enzyme, typically a β-Galactosidase; and a lactase dissolution-enhancing amount of a compressible sugar component (typically an agglomeration of sucrose and a second ingredient produced according to a co-crystallization process of a supersaturated sucrose solution and a second ingredient (the second ingredient is typically maltodextrin)) and fructose wherein the compressible sugar component and the fructose enhance the dissolution of the lactase component.
[0003] Yet another embodiment of the present invention is generally directed toward a rapidly disintegrating solid oral dosage form that includes a lactase component having a lactase enzyme in an amount sufficient to relieve one or more symptoms of lactose intolerance in a human when the human ingests the solid oral dosage form; a disintegrant, typically a carboxymethylcellulose calcium; a compressible sugar component; a fructose; a binder; a glidant; and a lubricant. The fructose and compressible sugar component are present together in an amount effective to enhance the dissolution of the lactase enzyme.
[0004] Another embodiment of the present invention is generally directed toward a method of making a lactase solid oral dosage form having enhanced disintegration. The method typically includes the following steps and possibly others, but could consist essentially of the following steps: adding all initial dry tableting ingredients that will make up the lactase solid oral dosage form to a mixing apparatus by cross-blending the initial dry tableting ingredients or combining the initial dry tableting ingredients together; mixing the initial dry tableting ingredients together in the mixing apparatus; adding a lubricant to the initial dry tableting ingredients to form a final tableting mix; and forming the lactase solid oral dosage form having enhanced disintegration from the final tableting mix; and wherein the initial dry tableting ingredients include a lactase component, a compressible sugar component and fructose. The compressible sugar component and fructose synergistically work together to enhance the dissolution of the lactase solid oral dosage form.
[0005] Yet another embodiment of the present invention is generally directed toward a method for enhancing the dissolution of a hydrophilic active, typically a lactase enzyme containing component, in a dry blended and subsequently directly compressed solid oral dosage form by the incorporation of a compressible sucrose component and a fructose into the dry blended tableting mix where the compressible sucrose component and the fructose are present in a synergistically effective amount such that the dissolution of the final dosage form is enhanced versus the same dry blended and subsequently directly compressed solid oral dosage form that does not contain both the compressible sucrose component and the fructose.
[0006] Another embodiment of the present invention is generally directed toward a rapidly disintegrating solid oral dosage form consisting essentially of or consisting of: a lactase component having a lactase enzyme in an amount sufficient to relieve one or more symptoms of lactose intolerance in a human when the human ingests the solid oral dosage form; a disintegrant, typically carboxymethylcellulose calcium; a compressible sugar component; a fructose; a binder; a glidant; and a lubricant; where the fructose and compressible sugar component are present together in an amount effective to enhance the dissolution of the lactase enzyme.
[0007] These and other features, advantages, and objects of the present invention will be further understood and appreciated by those skilled in the art by reference to the following specification and claims.
DETAILED DESCRIPTION
[0008] An embodiment of the present invention generally includes a supplement, typically a tablet, caplet, or other solid oral dosage form, that contains compressible sugar, carboxymethylcellulose calcium, and fructose as disintegrants as well as microcrystalline cellulose as a binder/diluent, a glidant such as colloidal silicon dioxide, a lubricant, typically magnesium stearate, and an active, typically lactase. It is presently believed that the compressible sugar and the fructose, in particular the incorporation of fructose, behave as disintegrants in the supplements as opposed to functioning simply as diluents. In this case, fructose was surprisingly found to improve disintegration properties of the hydrophilic active(s), in particular lactase. As a result, the supplement exhibits rapid release of the active. The supplement does not typically contain a superdisintegrants or a sugar alcohol.
[0009] In one particular preferred embodiment the active is lactase (an enzyme essential for digestion of lactose in milk and other dairy products such as ice cream and yogurt). In this embodiment of the present invention the lactase component is typically present in an amount of at least about 122.3 mg per caplet/tablet (about 30% to about 31%, more typically about 30.56% by weight). The lactase component itself typically includes: β-Galactosidase in an amount of about 65% by weight of the lactase component; carboxymethylcellulose calcium in an amount of about 20% by weight of the lactase component; glucose in an amount of about 10% of the lactase component; and sodium citrate in an amount of about 5% of the lactase component. The lactase component is typically a preblend of materials.
[0010] Typically, the remainder of a lactase tablet produced according to an embodiment of the present invention will include about 146 mg (about 36% by weight) of a compressible sugar component (DiPac® - direct compacting sucrose), which contains maltodextrin in an amount about 3.5% by weight of the compressible sugar component and 96.5% sucrose; about 5.8 mg (about 1.4% to about 1.5%, more typically about 1.45% by weight) carboxymethylcellulose calcium that is not a part of the lactose component but in addition to any carboxymethylcellulose calcium present in the lactase component; about 20 mg (about 4.5% to about 5.5%, more typically about 5% by weight) crystalline fructose, more typically crystalline, unmodified for direct compression fructose; about 4 mg (about 0.8% to about 1.2%, more typically about 1.0% by weight) colloidal silicon dioxide (Cab-O-Sil® M-5P); about 100 mg (about 23% to about 27%, more typically about 25% by weight) microcrystalline cellulose (binder or combination binders); and about 2.0 mg (from about 0.4% to about 0.5%, more typically about 0.5% by weight) magnesium stearate (or any lubricant or combination of lubricants suitable for tableting). The overall tablet weight may be from about 380 mg to about 420 mg, more typically from about 384 mg to about 416 mg, or even more typically about 400 mg or exactly 400 mg. The amount of active lactase typically is within the range of from about 9000 to about 14,850 Units/solid oral dosage form.
[0011] Typically, the solid dosage form, usually a caplet or tablet, may be produced by first weighing all of the ingredients. Next, all of the dry materials except the lubricant(s), which is typically magnesium stearate, are added to a mixer through a #16 US Mesh screen. The materials may optionally be either cross-blended or combined together and thereafter mixed with one another. Once thoroughly mixed, approximately 150 revolutions in a 75 cubic foot PK mixer (about 10 to about 15 minutes), the magnesium stearate or other lubricant(s) are passed through the #16 US Mesh screen and added to the mix and the mixture is further mixed for 30 revolutions (about 2 to about 2-1/2 minutes) to form a final tableting mix. When caplets are formed, the caplets are about 0.255 inch by 0.575 inch. The thickness is typically from about 0.180 inch to about 0.2 inch. The hardness is typically about 7 SCU to about 12 SCU, more typically about 10 SCU. The friability of the cap let is typically no more than 1% weight loss after 4 minutes (20 tablets).
[0012] The compressible sugar component (direct compacting sucrose) typically contains not less than 95.0% and not more than 98.0% sucrose, but could optionally be up to 100% sucrose or about 100% sucrose. The compressible sugar component may contain minor amounts of starch, maltodextrin (a hydrolyzed starch), or invert sugar, and may contain suitable lubricant, but should not typically contain less than 95.0% sucrose. One compressible sugar component of the present invention is DiPac® Direct Compacting & Tableting Sugar from Domino Foods, Inc. of Yonkers, New York and manufactured by American Sugar Refining, Inc. The DiPac® Direct Compacting & Tableting Sugar is a dry fondant sugar manufactured by co-crystallization that involves the spontaneous crystallization of supersaturated sucrose solution and a second ingredient, typically maltodextrin or other partially hydrolyzed (corn) starch, by agitating it while cooling. Maltodextrin typically has a Dextrose Equivalent (DE) of less than 20 and is produced by the enzymatic hydrolyzation of a starch, typically cornstarch in this case. The DiPac® Direct Compacting & Tableting Sugar is highly inert and will not react with moist active ingredients. The DiPac® Direct Compacting & Tableting Sugar also contains no invert sugar and has less than 1% moisture.
[0013] The compressible sugar component will typically have the following size distribution: 3% maximum retained on a #40 (425 μm) US Mesh; 75% minimum through a #100 (150 μm) US Mesh; and 8% maximum through a #200 (75 μm) US Mesh. The sucrose portion of compressible sugar is water-soluble. The compressible sugar typically has a melting point of about 186 degrees Celsius. Finally, compressible sugar typically has a specific surface area of from 0.13-0.14 m2/g. [0014] The fructose of the present invention typically contains a minimum of about 99.5% fructose and a maximum of 0.05% moisture. The fructose will typically have the following size distribution: 0.3% maximum retained on a #20 US Mesh screen; 1.0% maximum retained on a #30 US Mesh screen; 20% maximum retained on a #40 US Mesh screen; 45% minimum to 75% maximum retained on a #60 US Mesh screen; and 8.0% maximum percent through a #100 US Mesh screen. The fructose typically has a loose bulk density of 0.80-0.88 gm/ml.
[0015] It is presently believed that the compressible sugar and the fructose provide enhanced disintegration of the solid oral dosage form, typically a caplet or tablet. In particular, Applicant surprisingly discovered that fructose enhances the dissolution of hydrophilic actives, in particular lactase. Compressible sugar and fructose are conventionally utilized as diluents or sweeteners in tablet formulations. In particular, it was surprisingly discovered that these two components seem to behave synergistically in the presence of one another in a solid dosage form, to facilitate disintegration of the tablet/caplet or other solid dosage form containing the hydrophilic active or hydrophilic actives.
[0016] Carboxymethylcellulose calcium is a disintegrant that works in conjunction with the compressible sugar/fructose. Carboxymethylcellulose calcium is hygroscopic and usually has a particle distribution of 95% through a 73.7 μm sieve (#200 Mesh).
[0017] The microcrystalline cellulose is a purified, partially depolymerized cellulose. It is practically insoluble in water.
[0018] CAB-O-SIL®, from Cabot Corporation, is an untreated amorphous fumed silica that is a high purity silica manufactured by high temperature hydrolysis of chlorosilanes in a hydrogen/oxygen flame. Colloidal silicon dioxides have extremely small particle sizes and varying surface areas. The typical colloidal silicon dioxide used in an embodiment of the present invention has a particle size of from 0.2-0.3 microns and a surface area of from 200 ±25 m2/g.
[0019] Lactase produced commercially can be extracted both from yeasts such as
Kluyveromyces fragilis and Kluyveromyces lactis and from fungi, such as Aspergillus niger and Aspergillus oryzae. Typically, the lactase used in accordance with the present invention is extracted from Aspergillus oryzae. The lactase used in a lactase supplement embodiment of the present invention is typically hydrophilic. The lactase enzyme is typically β-Galactosidase. [0020] As discussed above, it is presently believed that the solid oral dosage forms, in particular lactase solid oral dosage forms, that incorporate the combination of ingredients discussed above have synergistic dissolution rates and an improved release profile for the amount of active material. In particular, based on initial testing, when compared with other lactase supplements currently on the market, compositions of the present invention at least have a faster initial dissolution rate in the first one minute to five minute time frame and have a greater overall dissolution of the active on and after 45 minutes.
Table I
Figure imgf000007_0001
[0021] Product A contained the following ingredients: lactase, microcrystalline cellulose, croscarmellose sodium, crospovidone, colloidal silicon dioxide, and magnesium stearate.
[0022] Product D contained the following ingredients: mannitol (70.2% by weight); microcrystalline cellulose (17.8% by weight); lactase (7.2% by weight); carboxymethylcellulose calcium (2.2% by weight); glucose (1.1% by weight); magnesium stearate (1.0% by weight); and sodium citrate (0.5% by weight).
[0023] The Example of Table I is an embodiment of the present invention and contains the following ingredients in approximately the following amounts: sucrose (about 35.2% by weight); microcrystalline cellulose (about 25% by weight); lactase enzyme (about 19.9% by weight); carboxymethylcellulose calcium (about 7.6% by weight); fructose (about 5% by weight); glucose (about 3.1% by weight); sodium citrate (about 1.5% by weight); maltodextrin (about 1.3% by weight); silicon dioxide (about 1% by weight) and magnesium stearate (about 0.5% by weight). [0024] The above data was produced according to the following method:
[0025] Method
[0026] Dissolution and Analysis Procedure:
[0027] The test method combines the FCC test method for Lactase Enzyme Activity with the USP Dissolution Performance testing as a means to measure the rate of performance of the lactase enzyme. The FCC reference method is: Food Chemical Codex (FCC); Fifth Edition; General Tests and Assays, Appendix V, Pages 913-914; Lactase (Acid) Beta- Galactosidase Activity. The USP dissolution reference method is: USP 30/NF 25 Volume 1; 2007; <711 dissolution Apparatus 1.
[0028] Aliquots were withdrawn at the following time points: 30 seconds, 60 seconds, 90 seconds, 5 minutes, 10 minutes, 30 minutes, 45 minutes, and 60 minutes.
[0029] The dissolution and the analysis of the aliquots withdrawn at each time point are analyzed according to the following procedure:
[0030] The method determines lactase (β-Galactosidase) activity in dietary supplements.
[0031] The assay is based on a 15-min hydrolysis of an o-nitrophenyl-B-D- galactopyranoside substrate at 37°C and pH 4.5. The o-nitrophenol released on hydrolysis of the o-nitrophenyl-B-D-galactopyranoside substrate is determined spectrophotometrically.
[0032] The time points were grouped and the aliquots withdrawn according to the following testing matrix:
[0033] 30 Second, 60 Second, and 90 Second Time Points:
[0034] 1. A fresh tablet of one product is placed in the dissolution vessel.
[0035] 2. The tablet is allowed to sink to the bottom of the vessel.
[0036] 3. Once the tablet is on the bottom of the vessel, the blade is rotated and the timing device started.
[0037] 4. At 30 seconds, 5 mL aliquot of the solution is pulled out and transferred to a 100 mL volumetric flask.
[0038] 5. Using separate flasks, repeat steps 1-4 at 60 and 90 seconds.
[0039] 6. Repeat steps 1-5 for a total of 3 replicate analyses per tablet. The average of the three analyses is shown in the above chart.
[0040] 7. The procedure (steps 1-6) is repeated for each version of tablet.
[0041] 5 Minute, 10 Minute, and 30 Minute Time Points:
[0042] 1. A fresh tablet of 1 product is placed in the dissolution vessel.
[0043] 2. The tablet is allowed to sink to the bottom of the vessel. [0044] 3. Once the tablet is on the bottom of the vessel, the blade is rotated and the timing device started. [0045] 4. At 5 minutes, 5 mL aliquot of the solution is pulled out and transferred to a 100 mL volumetric flask.
[0046] 5. Using separate flasks, repeat steps 1-4 at 10 minutes and 30 minutes.
[0047] 6. Repeat steps 1-5 for a total of 3 replicate analyses per tablet. The number reported in the chart above is the average of the results. [0048] 7. The procedure (steps 1-6) is repeated for each tablet.
[0049] 45 Minute and 60 Minute Time Points:
[0050] 1. A fresh tablet of 1 product is placed in the dissolution vessel.
[0051] 2. The tablet is allowed to sink to the bottom of the vessel.
[0052] 3. Once the tablet is on the bottom of the vessel, the blade is rotated and the timing device started. [0053] 4. At 45 minutes, 5 mL aliquot of the solution is pulled out and transferred to a 100 mL volumetric flask.
[0054] 5. Using separate flasks, repeat steps 1-4 at 60 minutes.
[0055] 6. Repeat steps 1-5 for a total of 3 replicate analyses per tablet tested. The number reported in the chart above is the average of the results. [0056] 7. The procedure (steps 1-6) is repeated for each tablet.

Claims

CLAIMS What is claimed is:
1. A rapidly disintegrating solid oral dosage form comprising: a lactase component containing a lactase supplemental effective amount of a lactase enzyme; and a lactase dissolution-enhancing amount of a compressible sugar component and fructose wherein the compressible sugar component and the fructose enhance the dissolution of the lactase component.
2. The rapidly disintegrating solid oral dosage form of claim 1 further comprising a disintegrant, a binder, and a glidant that are separately added from any disintegrant, binder or glidant present in the lactase component or present in the sugar component.
3. The solid dosage form of claim 2, wherein the overall weight of the solid dosage form is from about 380mg to about 420mg and the disintegrant comprises carboxymethylcellulose calcium.
4. The solid dosage form of claim 3, wherein the lactase component is present in an amount of from about 30% to about 31% by weight of the rapidly disintegrating solid oral dosage form; the compressible sugar component is present in an amount of about 36% by weight of the rapidly disintegrating solid oral dosage form; and the fructose is present in an amount of from about 4.5% to about 5.5% by weight of the rapidly disintegrating solid oral dosage form.
5. The rapidly disintegrating solid oral dosage form of claim 1 , wherein the lactase component is present in an amount of from about 30% to about 31% by weight of the rapidly disintegrating solid oral dosage form; the compressible sugar component is present in an amount of about 36% by weight of the rapidly disintegrating solid oral dosage form; and the fructose is present in an amount of from about 4.5% to about 5.5% by weight of the rapidly disintegrating solid oral dosage form.
6. The rapidly disintegrating solid oral dosage form of claim 1 , wherein the overall tablet weight is from about 380mg to about 420mg, the lactase component is present in an amount of from about 30% to about 31% by weight of the rapidly disintegrating solid oral dosage form; the compressible sugar component is present in an amount of about 36% by weight of the rapidly disintegrating solid oral dosage form; and the fructose is present in an amount of from about 4.5% to about 5.5% by weight of the rapidly disintegrating solid oral dosage form.
7. The rapidly disintegrating solid oral dosage form of claim 2, wherein the lactase component is present in an amount of from about 30% to about 31% by weight of the rapidly disintegrating solid oral dosage form; the compressible sugar component is present in an amount of about 36% by weight of the rapidly disintegrating solid oral dosage form; and the fructose is present in an amount of from about 4.5% to about 5.5% by weight of the rapidly disintegrating solid oral dosage form; the disintegrant that is separately added from any disintegrant that may be present in the lactase component or that may be present in the sugar component is carboxymethylcellulose calcium that is present in an amount of from about 1.4% to about 1.5% by weight of the rapidly disintegrating solid oral dosage form.
8. The rapidly disintegrating solid oral dosage form of claim 1 , wherein the average lactase units dissolved at 90 seconds and five minutes include: at least 3800 lactase units dissolved at five minutes and at least 1311 lactase units dissolved at 90 seconds and wherein the rapidly disintegrating solid oral dosage form is free of sugar alcohols and free of superdisintegrants and wherein the rapidly disintegrating solid oral dosage form is free of any preblends containing microcrystalline cellulose.
9. The rapidly disintegrating solid oral dosage form of claim 2, wherein the average lactase units dissolved at 90 seconds and five minutes include: at least 3800 lactase units dissolved at five minutes and at least 1311 lactase units dissolved at 90 seconds and wherein the rapidly disintegrating solid oral dosage form is free of sugar alcohols and free of superdisintegrants and wherein the rapidly disintegrating solid oral dosage form is free of any preblends containing microcrystalline cellulose.
10. The rapidly disintegrating solid oral dosage form of claim 7, wherein the average lactase units dissolved at 90 seconds and five minutes include: at least 3800 lactase units dissolved at five minutes and at least 1311 lactase units dissolved at 90 seconds and wherein the rapidly disintegrating solid oral dosage form is free of sugar alcohols and free of superdisintegrants and wherein the rapidly disintegrating solid oral dosage form is free of any preblends containing microcrystalline cellulose.
11. The rapidly disintegrating solid oral dosage form of claim 1 , wherein the average lactase units dissolved at 90 seconds and five minutes include: at least 3800 lactase units dissolved at five minutes and at least 1311 lactase units dissolved at 90 seconds.
12. The rapidly disintegrating solid oral dosage form of claim 2, wherein the average lactase units dissolved at 90 seconds and five minutes include: at least 3800 lactase units dissolved at five minutes and at least 1311 lactase units dissolved at 90 seconds.
13. The rapidly disintegrating solid oral dosage form of claim 7, wherein the average lactase units dissolved at 90 seconds and five minutes include: at least 3800 lactase units dissolved at five minutes and at least 1311 lactase units dissolved at 90 seconds.
14. The rapidly disintegrating solid oral dosage form of claim 1 , wherein the lactase component comprises a plurality of elements including a lactase enzyme present in an amount of about 65% of the lactase component; carboxymethylcellulose calcium present in an amount of about 20% of the lactase component; glucose present in an amount of about 10% of the lactase component; and sodium citrate present in an amount of about 5% of the lactase component.
15. The rapidly disintegrating solid oral dosage form of claim 2, wherein the lactase component comprises a plurality of elements including a lactase enzyme present in an amount of about 65% of the lactase component; carboxymethylcellulose calcium present in an amount of about 20% of the lactase component; glucose present in an amount of about 10% of the lactase component; and sodium citrate present in an amount of about 5% of the lactase component.
16. The rapidly disintegrating solid oral dosage form of claim 7, wherein the lactase component comprises a plurality of elements including a lactase enzyme present in an amount of about 65% of the lactase component; carboxymethylcellulose calcium present in an amount of about 20% of the lactase component; glucose present in an amount of about 10% of the lactase component; and sodium citrate present in an amount of about 5% of the lactase component.
17. The rapidly disintegrating solid oral dosage form of any of the previous claims, wherein the lactase component comprises a lactase enzyme that is β-Galactosidase.
18. The rapidly disintegrating solid oral dosage form of any of claims 1-16, wherein the fructose comprises a crystalline, unmodified fructose, the compressible sugar component is an agglomerated combination of sucrose and maltodextrin and the rapidly disintegrating solid oral dosage form is free of sugar alcohols and free of superdisintegrants and wherein the lactase component is free of microcrystalline cellulose.
19. The rapidly disintegrating solid oral dosage form of claim 17, wherein the fructose comprises a crystalline, unmodified fructose, the compressible sugar component is an agglomerated combination of sucrose and maltodextrin and the rapidly disintegrating solid oral dosage form is free of sugar alcohols and free of superdisintegrants and wherein the lactase component is free of microcrystalline cellulose.
20. The rapidly disintegrating solid oral dosage form of claim 1 , wherein the rapidly disintegrating solid oral dosage form is administered to a human for controlling the symptoms of lactose intolerance in the human.
21. The rapidly disintegrating solid oral dosage form of claim 20, wherein the human is a patient that has been diagnosed as having lactose intolerance.
22. A rapidly disintegrating solid oral dosage form comprising: a lactase component having a lactase enzyme in an amount sufficient to relieve one or more symptoms of lactose intolerance in a human when the human ingests the solid oral dosage form; a carboxymethylcellulose calcium; a compressible sugar component; a fructose; a binder; a glidant; a lubricant; and wherein the fructose and compressible sugar component are present together in an amount effective to enhance the dissolution of the lactase enzyme.
23. The rapidly disintegrating solid oral dosage form of claim 22, wherein the rapidly disintegrating solid oral dosage form is free of superdisintegrants.
24. The rapidly disintegrating solid oral dosage form of claim 22, wherein the rapidly disintegrating solid oral dosage form is free of sugar alcohol compounds.
25. The rapidly disintegrating solid oral dosage form of claim 23, wherein the rapidly disintegrating solid oral dosage form is free of sugar alcohol compounds.
26. The rapidly disintegrating solid oral dosage form of claim 22, wherein lactase component is free of microcrystalline cellulose.
27. The rapidly disintegrating solid oral dosage form of claim 23, wherein lactase component is free of microcrystalline cellulose.
28. The rapidly disintegrating solid oral dosage form of claim 24, wherein lactase component is free of microcrystalline cellulose.
29. The rapidly disintegrating solid oral dosage form of claim 22, wherein the lactase component comprises from about 30% to about 31% by weight of the solid oral dosage form; the carboxymethylcellulose calcium is separately added from any disintegrant, binder or glidant present in the lactase component or present in the sugar component and the separately added carboxymethylcellulose calcium comprises from about 1.4% to about 1.5% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; the binder comprises from about 23% to about 27% by weight of the solid oral dosage form; the glidant comprises from about 0.8% to about 1.2% by weight of the solid oral dosage form; and the lubricant comprises from about 0.4% to about 0.5% by weight of the solid oral dosage form.
30. The rapidly disintegrating solid oral dosage form of claim 23, wherein the lactase component comprises from about 30% to about 31% by weight of the solid oral dosage form; the carboxymethylcellulose calcium is separately added from any disintegrant, binder or glidant present in the lactase component or present in the sugar component and the separately added carboxymethylcellulose calcium comprises from about 1.4% to about 1.5% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; the binder comprises from about 23% to about 27% by weight of the solid oral dosage form; the glidant comprises from about 0.8% to about 1.2% by weight of the solid oral dosage form; and the lubricant comprises from about 0.4% to about 0.5% by weight of the solid oral dosage form.
31. The rapidly disintegrating solid oral dosage form of claim 24, wherein the lactase component comprises from about 30% to about 31% by weight of the solid oral dosage form; the carboxymethylcellulose calcium is separately added from any disintegrant, binder or glidant present in the lactase component or present in the sugar component and the separately added carboxymethylcellulose calcium comprises from about 1.4% to about 1.5% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; the binder comprises from about 23% to about 27% by weight of the solid oral dosage form; the glidant comprises from about 0.8% to about 1.2% by weight of the solid oral dosage form; and the lubricant comprises from about 0.4% to about 0.5% by weight of the solid oral dosage form.
32. The rapidly disintegrating solid oral dosage form of claim 25, wherein the lactase component comprises from about 30% to about 31% by weight of the solid oral dosage form; the carboxymethylcellulose calcium is separately added from any disintegrant, binder or glidant present in the lactase component or present in the sugar component and the separately added carboxymethylcellulose calcium comprises from about 1.4% to about
1.5% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; the binder comprises from about 23% to about 27% by weight of the solid oral dosage form; the glidant comprises from about 0.8% to about 1.2% by weight of the solid oral dosage form; and the lubricant comprises from about 0.4% to about 0.5% by weight of the solid oral dosage form.
33. The rapidly disintegrating solid oral dosage form of claim 26, wherein the lactase component comprises from about 30% to about 31% by weight of the solid oral dosage form; the carboxymethylcellulose calcium is separately added from any disintegrant, binder or glidant present in the lactase component or present in the sugar component and the separately added carboxymethylcellulose calcium comprises from about 1.4% to about 1.5% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; the binder comprises from about 23% to about 27% by weight of the solid oral dosage form; the glidant comprises from about 0.8% to about 1.2% by weight of the solid oral dosage form; and the lubricant comprises from about 0.4% to about 0.5% by weight of the solid oral dosage form.
34. The rapidly disintegrating solid oral dosage form of claim 27, wherein the lactase component comprises from about 30% to about 31% by weight of the solid oral dosage form; the carboxymethylcellulose calcium is separately added from any disintegrant, binder or glidant present in the lactase component or present in the sugar component and the separately added carboxymethylcellulose calcium comprises from about 1.4% to about 1.5% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; the binder comprises from about 23% to about 27% by weight of the solid oral dosage form; the glidant comprises from about 0.8% to about 1.2% by weight of the solid oral dosage form; and the lubricant comprises from about 0.4% to about 0.5% by weight of the solid oral dosage form.
35. The rapidly disintegrating solid oral dosage form of claim 28, wherein the lactase component comprises from about 30% to about 31% by weight of the solid oral dosage form; the carboxymethylcellulose calcium is separately added from any disintegrant, binder or glidant present in the lactase component or present in the sugar component and the separately added carboxymethylcellulose calcium comprises from about 1.4% to about 1.5% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; the binder comprises from about 23% to about 27% by weight of the solid oral dosage form; the glidant comprises from about 0.8% to about 1.2% by weight of the solid oral dosage form; and the lubricant comprises from about 0.4% to about 0.5% by weight of the solid oral dosage form.
36. The rapidly disintegrating solid oral dosage form of claims 29-35, wherein the binder comprises microcrystalline cellulose, the glidant comprises colloidal silicon dioxide, the lubricant comprises magnesium stearate; and the lactase enzyme is β-Galactosidase.
37. The rapidly disintegrating solid oral dosage form of claims 29-35, wherein the average lactase units dissolved at 90 seconds and five minutes comprise at least 3800 lactase units dissolved at five minutes and at least 1311 lactase units dissolved at 90 seconds.
38. A method of treating or controlling the symptoms of lactose intolerance comprising the step of administering the rapidly disintegrating solid oral dosage form of any of the preceding claims to a human.
39. A method of reducing the symptoms of lactose intolerance comprising the step of administering the rapidly disintegrating solid oral dosage form of any of claims 1-37 to a human.
40. The method of claim 38, wherein the human is a patient diagnosed with a reduced ability to digest lactose naturally or an inability to digest lactose naturally.
41. The method of claim 38 , wherein the human has been diagnosed with a reduced ability to digest lactose naturally or an inability to digest lactose naturally.
42. The method of making a lactase solid oral dosage form having enhanced disintegration comprising the following steps: adding all initial dry tableting ingredients that will make up the lactase solid oral dosage form to a mixing apparatus by cross-blending the initial dry tableting ingredients or combining the initial dry tableting ingredients together; mixing the initial dry tableting ingredients together in the mixing apparatus; adding a lubricant to the initial dry tableting ingredients to form a final tableting mix; and forming the lactase solid oral dosage form having enhanced disintegration from the final tableting mix; and wherein the initial dry tableting ingredients include a lactase component, a compressible sugar component and fructose wherein the compressible sugar component and the fructose synergistically work together to enhance the dissolution of the lactase solid oral dosage form.
43. The method of claim 42, wherein the lactase solid dosage form having enhanced disintegration comprises a solid oral dosage form having a thickness of from about 0.180 inch to about 0.2 inch and a hardness of from about 7 SCU to about 12 SCU.
44. The method of claim 42, wherein the step of mixing the dry ingredients except the lubricant together in the mixing apparatus comprises mixing the dry ingredients except for the lubricant for at least about 150 revolutions in the mixing apparatus.
45. The method of claim 42, wherein the initial dry tableting ingredients does not include a lubricant.
46. The method of claim 42, wherein the initial dry tableting ingredients comprises: a lactase component having a lactase enzyme in an amount sufficient to relieve one or more symptoms of lactose intolerance in a human when the human ingests the solid oral dosage form; a disintegrant; a compressible sugar component; a fructose; a binder; a glidant; a lubricant; and wherein the fructose and compressible sugar component are present together in an amount effective to enhance the dissolution of the lactase enzyme.
47. The method of claim 42, wherein the solid oral dosage form is free of superdisintegrants .
48. The method of claim 42, wherein the solid oral dosage form is free of sugar alcohol compounds.
49. The method of claim 47, wherein the solid oral dosage form is free of sugar alcohol compounds.
50. The method of claim 42, wherein lactase component is free of microcrystalline cellulose.
51. The method of claim 47, wherein lactase component is free of microcrystalline cellulose.
52. The method of claim 46, wherein lactase component is free of microcrystalline cellulose.
53. The method of claim 46, wherein the lactase component comprises from about 30% to about 31% by weight of the solid oral dosage form; the binder comprises carboxymethylcellulose calcium that is separately added from any disintegrant, binder or glidant present in the lactase component or present in the sugar component and the separately added carboxymethylcellulose calcium comprises from about 1.4% to about 1.5% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; the binder comprises from about 23% to about 27% by weight of the solid oral dosage form; the glidant comprises from about 0.8% to about 1.2% by weight of the solid oral dosage form; and the lubricant comprises from about 0.4% to about 0.5% by weight of the solid oral dosage form.
54. The method of claim 47, wherein the lactase component comprises from about 30% to about 31% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; and the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; and wherein the compressible sugar comprises an agglomerated sucrose and maltodextrin wherein the sucrose comprises from about 96.25% to about 97.75% of the compressible sugar and maltodextrin comprises from about 2.25% to about 3.75% of the compressible sugar.
55. The method of claim 48, wherein the lactase component comprises from about 30% to about 31% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; and the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; and wherein the compressible sugar comprises an agglomerated sucrose and maltodextrin wherein the sucrose comprises from about 96.25% to about 97.75% of the compressible sugar and maltodextrin comprises from about 2.25% to about 3.75% of the compressible sugar.
56. The method of claim 47, wherein the lactase component comprises from about 30% to about 31% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; and the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; and wherein the compressible sugar comprises an agglomerated sucrose and maltodextrin wherein the sucrose comprises from about 96.25% to about 97.75% of the compressible sugar and maltodextrin comprises from about 2.25% to about 3.75% of the compressible sugar.
57. The method of claim 50, wherein the lactase component comprises from about 30% to about 31% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; and the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; and wherein the compressible sugar comprises an agglomerated sucrose and maltodextrin wherein the sucrose comprises from about 96.25% to about 97.75% of the compressible sugar and maltodextrin comprises from about 2.25% to about 3.75% of the compressible sugar.
58. The method of claim 51 , wherein the lactase component comprises from about
30% to about 31% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; and the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; and wherein the compressible sugar comprises an agglomerated sucrose and maltodextrin wherein the sucrose comprises from about 96.25% to about 97.75% of the compressible sugar and maltodextrin comprises from about 2.25% to about 3.75% of the compressible sugar.
59. The method of claim 52, wherein the lactase component comprises from about 30% to about 31% by weight of the solid oral dosage form; the binder comprises carboxymethylcellulose calcium that is separately added from any disintegrant, binder or glidant present in the lactase component or present in the sugar component and the separately added carboxymethylcellulose calcium comprises from about 1.4% to about 1.5% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; the binder comprises from about 23% to about 27% by weight of the solid oral dosage form; the glidant comprises from about 0.8% to about 1.2% by weight of the solid oral dosage form; and the lubricant comprises from about 0.4% to about 0.5% by weight of the solid oral dosage form.
60. The method of claims 46-52, wherein the binder comprises microcrystalline cellulose, the glidant comprises colloidal silicon dioxide, the lubricant comprises magnesium stearate; and the lactase enzyme is β-Galactosidase.
61. A method of enhancing the dissolution of a hydrophilic active in a dry blended and subsequently directly compressed solid oral dosage form by the incorporation of a directly compressible sucrose component and a fructose into the dry blended tableting mix wherein the sucrose component and the fructose are present in a synergistically effective amount such that the dissolution of the final dosage form is enhanced versus the same dry blended and subsequently directly compressed solid oral dosage form but not containing both the compressible sucrose component and the fructose.
62. The method of claim 61, wherein the hydrophilic active is a lactase enzyme or a mixture of lactase enzymes.
63. A rapidly disintegrating solid oral dosage form consisting essentially of: a lactase component having a lactase enzyme in an amount sufficient to relieve one or more symptoms of lactose intolerance in a human when the human ingests the solid oral dosage form; a disintegrant; a compressible sugar component; a fructose; a binder; a glidant; a lubricant; and wherein the fructose and compressible sugar component are present together in an amount effective to enhance the dissolution of the lactase enzyme.
64. The rapidly disintegrating solid oral dosage form of claim 63, wherein the lactase component comprises from about 30% to about 31% by weight of the solid oral dosage form; the disintegrant comprises carboxymethylcellulose calcium that is separately added from any disintegrant, binder or glidant present in the lactase component or present in the sugar component and the separately added carboxymethylcellulose calcium comprises from about 1.4% to about 1.5% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; the binder comprises from about 23% to about 27% by weight of the solid oral dosage form; the glidant comprises from about 0.8% to about 1.2% by weight of the solid oral dosage form; and the lubricant comprises from about 0.4% to about 0.5% by weight of the solid oral dosage form.
65. The rapidly disintegrating solid oral dosage form of claim 64, wherein the sugar component is an agglomerated sucrose and maltodextrin wherein the sucrose is present in an amount of from about 96.25% to about 97.75% of the compressible sugar component and maltodextrin is present in an amount of from about 2.25% to about 3.75% of the compressible sugar component.
66. A rapidly disintegrating solid oral dosage form consisting of: a lactase component having a lactase enzyme in an amount sufficient to relieve one or more symptoms of lactose intolerance in a human when the human ingests the solid oral dosage form; a disintegrant; a compressible sugar component; a fructose; a binder; a glidant; a lubricant; and wherein the fructose and compressible sugar component are present together in an amount effective to enhance the dissolution of the lactase enzyme.
67. The rapidly disintegrating solid oral dosage form of claim 66, wherein the lactase component comprises from about 30% to about 31% by weight of the solid oral dosage form; the disintegrant comprises carboxymethylcellulose calcium that is separately added from any disintegrant, binder or glidant present in the lactase component or present in the sugar component and the separately added carboxymethylcellulose calcium comprises from about 1.4% to about 1.5% by weight of the solid oral dosage form; the compressible sugar comprises about 36% by weight of the solid oral dosage form; the fructose comprises from about 4.5% to about 5.5% by weight of the solid oral dosage form; the binder comprises from about 23% to about 27% by weight of the solid oral dosage form; the glidant comprises from about 0.8% to about 1.2% by weight of the solid oral dosage form; and the lubricant comprises from about 0.4% to about 0.5% by weight of the solid oral dosage form.
68. The rapidly disintegrating solid oral dosage form of claim 67, wherein the sugar component is an agglomerated sucrose and maltodextrin wherein the sucrose is present in an amount of from about 96.25% to about 97.75% of the compressible sugar component and maltodextrin is present in an amount of from about 2.25% to about 3.75% of the compressible sugar component.
PCT/US2009/064803 2008-11-17 2009-11-17 Fast-acting, dietary supplement containing compositions and methods of producing the compositions WO2010057188A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11532508P 2008-11-17 2008-11-17
US61/115,325 2008-11-17

Publications (2)

Publication Number Publication Date
WO2010057188A2 true WO2010057188A2 (en) 2010-05-20
WO2010057188A3 WO2010057188A3 (en) 2010-09-10

Family

ID=42170806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/064803 WO2010057188A2 (en) 2008-11-17 2009-11-17 Fast-acting, dietary supplement containing compositions and methods of producing the compositions

Country Status (1)

Country Link
WO (1) WO2010057188A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3241587A1 (en) * 2016-05-04 2017-11-08 Takabio Composition for food supplement

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192582A1 (en) * 2002-12-19 2004-09-30 Burnett Daniel R. Ingestible formulations for transient, noninvasive reduction of gastric volume
US20060013807A1 (en) * 2004-07-13 2006-01-19 Chapello William J Rapidly disintegrating enzyme-containing solid oral dosage compositions
EP1674083A1 (en) * 2003-10-15 2006-06-28 Fuji Chemical Industry Co., Ltd. Tablet quickly disintegrating in oral cavity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192582A1 (en) * 2002-12-19 2004-09-30 Burnett Daniel R. Ingestible formulations for transient, noninvasive reduction of gastric volume
EP1674083A1 (en) * 2003-10-15 2006-06-28 Fuji Chemical Industry Co., Ltd. Tablet quickly disintegrating in oral cavity
US20060013807A1 (en) * 2004-07-13 2006-01-19 Chapello William J Rapidly disintegrating enzyme-containing solid oral dosage compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FUKAMI, J. ET AL.: 'Evaluation of rapidly disintegrating tablets containing glycine and carboxymethylcellulose' INT. J. PHARM. vol. 301, 2006, pages 101 - 109 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3241587A1 (en) * 2016-05-04 2017-11-08 Takabio Composition for food supplement
FR3050907A1 (en) * 2016-05-04 2017-11-10 Takabio COMPOSITION FOR FOOD SUPPLEMENT

Also Published As

Publication number Publication date
WO2010057188A3 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
JP5352474B2 (en) Orally disintegrating tablet and method for producing the same
KR101554355B1 (en) Film-coated and/or granulated calcium-containing compounds and use thereof in pharmaceutical compositions
CN1193740C (en) Fast dispersing dosage forms free of gelatin
US9278063B2 (en) Press-coated orally-disintegrating tablets
JP5446716B2 (en) Method for producing tablets containing arginine and carnitine
JP2005522444A (en) Atovastatin formulation stabilized by addition of alkali metal
JPH05501260A (en) Direct compression carrier composition
JPH11113525A (en) Tableting of erythritol
EP0844881B1 (en) Laxative comprising lactitol and psyllium
HU227360B1 (en) Quickly decomposing pharmaceutical composition containing tramadol or a tramadol salt
EA015035B1 (en) Pre-compacted calcium-containing compositions
US4670251A (en) Microcrystalline tableting excipient derived from whey
WO2010057188A2 (en) Fast-acting, dietary supplement containing compositions and methods of producing the compositions
EP2433652B1 (en) Dry-coated orally-disintegrating tablet
JP2010254580A (en) Method for producing arginine-containing tablet
JP2010270111A (en) Arginine-containing tablet
EP2268266B1 (en) Process for obtaining powder compositions of orlistat to be filled into a capsule
EP1738755B1 (en) Tablet containing branched chain amino acid and process for producing the same
JP2000191517A (en) Granular composition whose unpalatable taste is masked and its production
CN101959505B (en) Improved isomalt-containing tablets and methods for the production thereof
WO1999030714A1 (en) Sustained-release theophylline preparation and process for producing the same
CN102836156A (en) Capsule containing flupirtine maleate and preparation method thereof
TW201431553A (en) Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]benzamide
AU2003100587A4 (en) Granulation of Colostrum Powder
US9675666B2 (en) Immediate-release tablet formulation, composition for tablets and method for manufacturing immediate-release tablet formulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09826975

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09826975

Country of ref document: EP

Kind code of ref document: A2